MARKET

AZN

AZN

AstraZeneca
NASDAQ

Real-time Quotes | Nasdaq Last Sale

47.16
-0.57
-1.19%
Pre Market: 47.54 +0.38 +0.81% 07:17 03/04 EST
OPEN
47.64
PREV CLOSE
47.73
HIGH
47.64
LOW
46.85
VOLUME
32.38K
TURNOVER
--
52 WEEK HIGH
64.94
52 WEEK LOW
36.15
MARKET CAP
123.82B
P/E (TTM)
38.75
1D
5D
1M
3M
1Y
5Y
Germany approves AstraZeneca for over-65s
reuters.com · 37m ago
Global Lysosomal Acid Liapse (LAL) Deficiency Treatment Market Outlook, Industry Analysis and Prospect 2020 -2026
Mar 04, 2021 (Heraldkeepers) -- The growing adoption of enzyme replacement therapy for treatment is one of the major factors driving the growth of global...
Heraldkeepers · 1h ago
EU to extend COVID vaccine export controls to end of June - sources
reuters.com · 1h ago
Implantable Drug-Eluting Devices Market 2021 Trends, Industry Demand, Growth, Top Leaders, Size Estimation, Business opportunities, Challenges and Outlook to 2029 | FMI Report
Mar 04, 2021 (MARKITWIRED via COMTEX) -- A recent market study published by Future Market Insights on the implantable drug-eluting devices market includes...
Markitwired · 1h ago
Emergent BioSolutions Capable Of Manufacturing 1B COVID-19 Vaccine Doses Annually, CEO Says
Emergent BioSolutions Inc (NYSE: EBS) has built the capacity to produce vaccines from AstraZeneca Plc (NASDAQ: 
Benzinga · 1h ago
Anxiety Disorder and Depression Treatment Market to grow at a rate of 2.4% from USD 15.85 billion
Market Insight Reports · 1h ago
OTC Cold and Cough Medicines Market 2020-2027: Sanofi-Aventis, Johnson & Johnson, Reckitt Benckiser Group Plc.
Comserve · 1h ago
Global Cholera Vaccines Market Outlook, Industry Analysis and Prospect 2016 -2027
Mar 04, 2021 (Heraldkeepers) -- COMTEX_382124794/2582/2021-03-04T05:54:52 Is there a problem with this press release? Contact the source provider Comtex at...
Heraldkeepers · 1h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AZN. Analyze the recent business situations of AstraZeneca through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AZN stock price target is 62.35 with a high estimate of 69.40 and a low estimate of 56.00.
EPS
Institutional Holdings
Institutions: 1.06K
Institutional Holdings: 410.99M
% Owned: 15.65%
Shares Outstanding: 2.63B
TypeInstitutionsShares
Increased
260
43.47M
New
206
10.36M
Decreased
218
68.33M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.99%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Non-Executive Chairman/Independent Director
Leif Johansson
Chief Executive Officer/Executive Director
Pascal Soriot
Chief Financial Officer/Executive Director
Marc Dunoyer
Chief Human Resource Officer/General Counsel
Jeffrey Pott
Executive Vice President/Chief Compliance Officer
Katarina Ageborg
Executive Vice President
Jose Baselga
Executive Vice President
Pam Cheng
Executive Vice President
Ruud Dobber
Executive Vice President
David Fredrickson
Executive Vice President
Menelas Pangalos
Executive Vice President
Iskra Reic
Executive Vice President
Leon Wang
Secretary
Adrian Kemp
Non-Executive Director
Euan Ashley
Non-Executive Director
Diana Layfield
Non-Executive Director
Tony Mok
Non-Executive Director
Marcus Wallenberg
Non-Executive Independent Director
Genevieve Berger
Non-Executive Director
Weiying Wang
Non-Executive Independent Director
Philip Broadley
Independent Director
Narayan Seshadri
Non-Executive Independent Director
Deborah DiSanzo
Non-Executive Independent Director
Graham Chipchase
Non-Executive Independent Director
Michel Demare
Non-Executive Independent Director
Deborah Eldracher
Non-Executive Independent Director
Sherilyn McCoy
Non-Executive Independent Director
Nazneen Rahman
Declaration Date
Dividend Per Share
Ex-Div Date
02/21/2021
Dividend USD 0.93
02/25/2021
07/30/2020
Dividend USD 0.44
08/13/2020
--
Dividend USD 0.93
02/27/2020
--
Dividend USD 0.44
08/08/2019
--
Dividend USD 0.93
02/28/2019
07/26/2018
Dividend USD 0.44
08/09/2018
02/02/2018
Dividend USD 0.93
02/15/2018
07/28/2017
Dividend USD 0.44
08/09/2017
03/14/2017
Dividend USD 0.93
02/15/2017
09/08/2016
Dividend USD 0.44
08/10/2016
02/25/2016
Dividend USD 0.93
02/17/2016
07/30/2015
Dividend USD 0.44
08/12/2015
02/24/2015
Dividend USD 0.94
02/18/2015
07/31/2014
Dividend USD 0.9
08/13/2014
02/07/2014
Dividend USD 1.9
02/19/2014
08/01/2013
Dividend USD 0.9
08/14/2013
About AZN
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Webull offers kinds of AstraZeneca plc (ADR) stock information, including NASDAQ:AZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AZN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AZN stock methods without spending real money on the virtual paper trading platform.